Searched for
PARP INHIBITOR
Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...- GSK re-enters India’s cancer drug marketGlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gyna...
- GSK enters into oncology segment; launches therapies for gynaecological cancersGlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. Thes...
- Zydus launches anti-cancer generic drug olaparib in IndiaThe drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for a more tailored and effective tre...
- New 3-in-1 blood test can transform the treatment of advanced prostate cancerThe test could help to extend or save lives, by targeting treatment more effectively.
- 'Combo therapy against ovarian, breast cancer can overcome drug resistance'Kolkata, Sep 26 (IANS) Bolstering the knowhow behind targeted cancer treatment, Indian scientists have offered a new rationale for combinat...
- New gene that increases risk of breast cancer identifiedWomen who carried rare mutations in PALB2 were found to have on average a one in three chance of developing breast cancer by the age of 70.
Load More